Senl-T7
Precursor T-Cell Acute Lymphoblastic Leukemia
Explore 7 assets in Precursor T-Cell Acute Lymphoblastic Leukemia →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Modality
Cell therapy
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05626400CT.gov Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Precursor T-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Senl-T7 (this asset) | Hebei Senlang Biotechnology Inc., Ltd. | N/A | D · 30 |
| Dexasone | Sanofi | P2 | B |
| Isatuximab | Sanofi | P2 | CCC |
| Cytarabine | First Affiliated Hospital of Zhejiang University | P2 | CCC |
| Ranitidine | Sanofi | P2 | CCC |
| Venetoclax | First Affiliated Hospital of Zhejiang University | P2 | CCC |
| Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester) | First Affiliated Hospital of Zhejiang University | P2 | CCC |
| Diphenhydramine | Sanofi | P2 | CCC |
| Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P1/2 | CCC |
+11 more in the Precursor T-Cell Acute Lymphoblastic Leukemia cohort
Other indications for Senl-T7
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | N/A | D · 30 |
| T Lymphoblastic Leukemia/Lymphoma | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Senl-T7 in Precursor T-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/senl-t7-precursor-t-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →